[go: up one dir, main page]

AR104194A1 - Composición del factor de von willebrand - Google Patents

Composición del factor de von willebrand

Info

Publication number
AR104194A1
AR104194A1 ARP160100927A ARP160100927A AR104194A1 AR 104194 A1 AR104194 A1 AR 104194A1 AR P160100927 A ARP160100927 A AR P160100927A AR P160100927 A ARP160100927 A AR P160100927A AR 104194 A1 AR104194 A1 AR 104194A1
Authority
AR
Argentina
Prior art keywords
von willebrand
willebrand factor
factor composition
composition
bleeding
Prior art date
Application number
ARP160100927A
Other languages
English (en)
Original Assignee
Lab Francais Du Fractionnement
Ct Hospitalier Univ De Lille
Univ Lille Ii Droit & Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement, Ct Hospitalier Univ De Lille, Univ Lille Ii Droit & Sante filed Critical Lab Francais Du Fractionnement
Publication of AR104194A1 publication Critical patent/AR104194A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composición del factor de von Willebrand para la prevención y/o el tratamiento de hemorragias y/o de sangrados en los pacientes bajo asistencia circulatoria mecánica.
ARP160100927A 2015-04-07 2016-04-06 Composición del factor de von willebrand AR104194A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1552982A FR3034669B1 (fr) 2015-04-07 2015-04-07 Nouvelle utilisation du facteur von willebrand

Publications (1)

Publication Number Publication Date
AR104194A1 true AR104194A1 (es) 2017-07-05

Family

ID=54014930

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100927A AR104194A1 (es) 2015-04-07 2016-04-06 Composición del factor de von willebrand

Country Status (11)

Country Link
US (2) US10478475B2 (es)
EP (1) EP3280436A1 (es)
JP (2) JP6636041B2 (es)
KR (1) KR20180016983A (es)
CN (1) CN107743395A (es)
AR (1) AR104194A1 (es)
AU (1) AU2016245156A1 (es)
CA (1) CA2980232A1 (es)
FR (2) FR3034669B1 (es)
TW (1) TW201642900A (es)
WO (1) WO2016162369A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020000322A2 (pt) * 2017-07-07 2020-07-14 Baxalta Incorporated uso de fator de von willebrand recombinante (rvwf)
EP3488858A1 (en) * 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies A von willebrand factor composition for use in treating a pathology mediated by angiogenesis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
US6518482B2 (en) 1994-09-13 2003-02-11 American National Red Cross Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor
DE60137950D1 (de) 2000-10-02 2009-04-23 Novo Nordisk Healthcare Ag Verfahren zur herstellung vitamin-k-abhängiger proteine
HRP20180962T1 (hr) 2011-06-10 2018-10-19 Baxalta GmbH Liječenje bolesti zgrušavanja primjenom rekombinantnog vwf
MY190257A (en) * 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
EP2662083A1 (en) * 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease

Also Published As

Publication number Publication date
JP6636041B2 (ja) 2020-01-29
CA2980232A1 (fr) 2016-10-13
US20180110838A1 (en) 2018-04-26
KR20180016983A (ko) 2018-02-20
EP3280436A1 (fr) 2018-02-14
JP2020097571A (ja) 2020-06-25
FR3034670A1 (fr) 2016-10-14
AU2016245156A1 (en) 2017-10-12
CN107743395A (zh) 2018-02-27
FR3034669A1 (fr) 2016-10-14
WO2016162369A1 (fr) 2016-10-13
US20200038489A1 (en) 2020-02-06
US10478475B2 (en) 2019-11-19
FR3034670B1 (fr) 2020-02-14
FR3034669B1 (fr) 2020-02-14
TW201642900A (zh) 2016-12-16
JP2018513858A (ja) 2018-05-31

Similar Documents

Publication Publication Date Title
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
DK3600281T3 (da) Kombinationsbehandling til behandling eller forebyggelse af tumorer
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
EP3399972A4 (en) LOW-DOSED THERAPEUTIC TREATMENT
PT3661514T (pt) Mavacamten para utilização no tratamento da cardiomiopatia hipertrófica
MX378273B (es) Compuestos activos hacia bromodominios.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6
EP3406224A4 (en) MEDICAL TISSUE
CL2019001339A1 (es) Inhibidores de la magl.
DK3474802T3 (da) Medicinsk forbinding
SI3346995T1 (sl) Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
EP3448263A4 (en) Electrotherapeutic treatment
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
DK3191103T3 (da) Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner
IL270978B (en) Grape skin for use in the treatment of dysbiosis
MA50358A (fr) Sémaglutide en thérapie médicale
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
CL2017000178A1 (es) Compuestos para usar en el tratamiento antihelmíntico
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
IT201600101413A1 (it) Composizione liquida per uso nel trattamento del reflusso gastroesofageo
EP3626256C0 (fr) Composition pour le traitement des lésions tissulaires
IT201600121617A1 (it) Composizione per il trattamento del reflusso gastroesofageo

Legal Events

Date Code Title Description
FB Suspension of granting procedure